Allergy Therapeutics sees revenue soar

Allergy Therapeutics sees revenue soar

Worthing-headquartered Allergy Therapeutics has seen revenue rise 12% over the past year to £48.5m after expanding its European presence.

Allergy Therapeutics is an international pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. 

The company sells proprietary products and third party products from its subsidiaries in nine major European markets and via distribution agreements in an additional 10 countries.

The firm has continued to expand its European footprint over the past year following the acquisition of Spanish firm Alerpharma, which has helped drive sales outside of its home market.

Looking to the future, chief executive Manuel Llobet has ambitious plans for the company which is continuing to invest in the development of new products and services.

He said: "This year has seen many events in the allergy market. I would like to highlight Allergy Therapeutics' revenue growth, now accounting for 12% of the share in our competitive market, and progressing well towards our long-term strategic plans with developments across all areas of the business.

“Our excellent products and outstanding team have delivered success in product development and marketing and, despite the requirement for our additional range-finding study, we look forward to capitalising on opportunities to continue growing into new markets and delivering patient-friendly, market-leading treatments, to help patients across the allergy spectrum.

“We are a thriving, visionary company, led by a self-driven team, totally committed to transforming allergy treatments. We are passionate about what we do and we are convinced that the best is yet to come."

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing with MHRA-approved manufacturing facilities. 

The company employs around 420 people and is listed on the London Stock Exchange.